Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions

[1]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[2]  B. Jönsson,et al.  Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study , 2020, JHEP reports : innovation in hepatology.

[3]  F. Sanai,et al.  Management of nonalcoholic fatty liver disease in the Middle East , 2020, World journal of gastroenterology.

[4]  V. Wong,et al.  NAFLD — sounding the alarm on a silent epidemic , 2020, Nature Reviews Gastroenterology & Hepatology.

[5]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[6]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[7]  S. Francque,et al.  Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Real‐Life Populations , 2019, Hepatology.

[8]  Robert P. Myers,et al.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.

[9]  Erin R. Cleveland,et al.  Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study , 2019, Journal of General Internal Medicine.

[10]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[11]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[12]  R. Perry,et al.  A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH) , 2019, Pharmacology research & perspectives.

[13]  S. Dombrowski,et al.  Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study , 2019, Translational behavioral medicine.

[14]  C. How,et al.  A practical clinical approach to liver fibrosis. , 2018, Singapore medical journal.

[15]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[16]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[17]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[18]  M. Trenell,et al.  Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  J. Piercy,et al.  Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015 , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[20]  R. Eckel,et al.  Statin Intolerance: A Literature Review and Management Strategies. , 2016, Progress in cardiovascular diseases.

[21]  J. Piercy,et al.  Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme , 2016, BMJ Open.

[22]  P. Thompson,et al.  Statin-Associated Side Effects. , 2016, Journal of the American College of Cardiology.

[23]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[24]  K. Corey,et al.  Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis , 2016, Digestive Diseases and Sciences.

[25]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[26]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[27]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[28]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[29]  S. Caldwell,et al.  Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand? , 2015, Digestive Diseases and Sciences.

[30]  G. Watts,et al.  Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? , 2014, Expert opinion on drug safety.

[31]  G. Sebastiani,et al.  Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. , 2014, Canadian journal of gastroenterology & hepatology.

[32]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification , 2013, Journal of Clinical Pathology.

[33]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[34]  H. Lee,et al.  Management of nonalcoholic fatty liver disease , 2013 .

[35]  A. McCullough,et al.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. , 2012, Gastroenterology & hepatology.

[36]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[37]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[38]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[39]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand , 2008, Current medical research and opinion.